Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals-Reference-Cited by-同舟云学术

Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals

Published:2022-04 Issue:4 Volume:25 Page:104076
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Mader Anna-Lena,Tydykov Leonid,Glück Vivian,Bertok Manuela,Weidlich Tanja,Gottwald Christine,Stefl Alexa,Vogel Matthias,Plentz Annelie,Köstler Josef,Salzberger Bernd,Wenzel Jürgen J.,Niller Hans Helmut,Jantsch Jonathan,Wagner Ralf,Schmidt Barbara,Glück Thomas,Gessner André,Peterhoff David^ORCID

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference43 articles.

1. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost;Ai;Emerg. Microbes Infect.,2021

2. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern;Andrews;medRxiv,2021

3. Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice;Asthagiri Arunkumar;J. Virol.,2019

4. Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies;Barnes;bioRxiv,2020

5. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies;Barnes;Nature,2020

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-07-20

2. A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants;Clinical Immunology;2024-03

3. Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses;Antiviral Research;2023-12

4. Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies;The Journal of Infectious Diseases;2023-11-23

5. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice;European Journal of Pharmaceutics and Biopharmaceutics;2023-11